Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2012

View Archived Issues

GlaxoSmithKline reviews second quarter 2012

Alla Chem patents novel receptor ligands

Curagenix synthesizes new inhibitors of Wnt signaling

New phase I-II data disclosed on renal cell carcinoma vaccine candidate

Genetically corrected human iPSC-derived mesoangioblast as potential muscular dystrophy therapy

Three-peptide vaccine for advanced esophageal cancer shows promise in phase I-II trials

New complement factor D inhibitors prepared at Novartis

Kinentia Biosciences presents new ERK-2/MMP-1 inhibitors

Eisai discloses new BACE1 inhibitors

Microbiotix receives grant to develop type III secretion inhibitors

OrPro Therapeutics awarded NIH grant to advance recombinant thioredoxin

BMS-986094 administration suspended in clinical trial

BromSite advances to phase III testing

Agios Pharmaceuticals divulges novel PKM2 activators

Hologic completes acquisition

BioTime subsidiary receives grant from Israeli government

Novel DLL4-directed antibodies reported

FDA accepts Bronchitol NDA for review

Novel antibodies designed by researchers in Cuba and Uruguay

First patients treated in two lung cancer trials evaluating ganetespib

Two investigator-sponsored cabozantinib trials begin

Asterand changes name

Diffusion Pharmaceuticals completes treatment in first cohort of phase I/II brain cancer trial

Studies of Cinryze/rHuPH20 combination placed on temporary hold

DBV Technologies kicks off phase IIb VIPES study

Acquisition of Human Genome Sciences complete

Additional funding supports development of Anthim

Oxygen Biotherapeutics and U.S. navy establish Oxycyte CRADA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...